Amphastar Pharmaceuticals, Inc. (AMPH): Price and Financial Metrics
Amphastar Pharmaceuticals, Inc. (AMPH)
Today's Latest Price: $18.12 USD
Updated Nov 27 1:00pm
Add AMPH to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 240 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
AMPH Stock Summary
- AMPH's went public 6.43 years ago, making it older than only 23.47% of listed US stocks we're tracking.
- With a price/earnings ratio of 127.65, Amphastar Pharmaceuticals Inc P/E ratio is greater than that of about 93.76% of stocks in our set with positive earnings.
- Over the past twelve months, AMPH has reported earnings growth of -81.43%, putting it ahead of only 22.91% of US stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Amphastar Pharmaceuticals Inc are LSCC, ALRM, SEDG, QLYS, and CORT.
- Visit AMPH's SEC page to see the company's official filings. To visit the company's web site, go to www.amphastar.com.
AMPH Stock Price Chart Interactive Chart >
AMPH Price/Volume Stats
| Current price | $18.12 | 52-week high | $22.69 |
| Prev. close | $17.87 | 52-week low | $12.32 |
| Day low | $17.51 | Volume | 140,645 |
| Day high | $18.34 | Avg. volume | 255,738 |
| 50-day MA | $19.59 | Dividend yield | N/A |
| 200-day MA | $18.75 | Market Cap | 860.77M |
Amphastar Pharmaceuticals, Inc. (AMPH) Company Bio
Amphastar Pharmaceuticals focuses on the development, manufacture, marketing, and sale of generic and proprietary injectable and inhalation products. It operates in two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients. The company was founded in 1996 and is based in Rancho Cucamonga, California.
AMPH Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $18.12 | $35.23 | 92% |
Below please find a table outlining a discounted cash flow forecast for AMPH, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Amphastar Pharmaceuticals Inc ranked in the 61th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 93% on a DCF basis. The most interesting components of our discounted cash flow analysis for Amphastar Pharmaceuticals Inc ended up being:
- The business' balance sheet reveals debt to be 7% of the company's capital (with equity being the remaining amount). Approximately merely 18.82% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
- The company's cost of debt, derived from its interest coverage, tax rate, and market capitalization, is greater than only 0% of stocks in its sector (Healthcare).
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | 88% |
| 1% | 90% |
| 2% | 92% |
| 3% | 94% |
| 4% | 96% |
| 5% | 98% |
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as AMPH, try CHE, ANTM, FMS, DVA, and ANIP.
Loading social stream, please wait...